110,225 Shares in Diplomat Pharmacy, Inc. (DPLO) Purchased by Sterling Capital Management LLC
Sterling Capital Management LLC purchased a new stake in Diplomat Pharmacy, Inc. (NYSE:DPLO) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 110,225 shares of the company’s stock, valued at approximately $2,283,000. Sterling Capital Management LLC owned about 0.16% of Diplomat Pharmacy at the end of the most recent quarter.
Several other large investors have also made changes to their positions in DPLO. Janus Henderson Group PLC purchased a new stake in Diplomat Pharmacy in the 2nd quarter worth about $67,476,000. Cortina Asset Management LLC raised its position in Diplomat Pharmacy by 538.8% in the 3rd quarter. Cortina Asset Management LLC now owns 1,616,792 shares of the company’s stock worth $33,484,000 after purchasing an additional 1,363,696 shares during the period. Northern Trust Corp raised its position in Diplomat Pharmacy by 95.1% in the 2nd quarter. Northern Trust Corp now owns 1,234,477 shares of the company’s stock worth $18,270,000 after purchasing an additional 601,834 shares during the period. Dimensional Fund Advisors LP raised its position in Diplomat Pharmacy by 149.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 894,669 shares of the company’s stock worth $18,528,000 after purchasing an additional 536,412 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in Diplomat Pharmacy in the 3rd quarter worth about $8,226,000. 72.48% of the stock is owned by hedge funds and other institutional investors.
A number of analysts recently weighed in on DPLO shares. Zacks Investment Research raised shares of Diplomat Pharmacy from a “hold” rating to a “strong-buy” rating and set a $24.00 price objective on the stock in a research report on Tuesday, October 10th. Robert W. Baird lowered shares of Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $24.00 to $18.00 in a research report on Thursday, November 16th. Leerink Swann raised shares of Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and set a $23.00 price objective on the stock in a research report on Monday, December 11th. Mizuho increased their price objective on shares of Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 7th. Finally, BidaskClub raised shares of Diplomat Pharmacy from a “hold” rating to a “buy” rating in a research report on Tuesday, September 26th. Five equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $20.72.
Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Monday, November 6th. The company reported $0.25 EPS for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.10. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.16 billion. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. The company’s quarterly revenue was down 4.8% compared to the same quarter last year. During the same period last year, the company posted $0.21 earnings per share. research analysts anticipate that Diplomat Pharmacy, Inc. will post 0.85 EPS for the current year.
In related news, CFO Atul Kavthekar bought 2,000 shares of Diplomat Pharmacy stock in a transaction dated Monday, November 20th. The shares were acquired at an average cost of $15.00 per share, with a total value of $30,000.00. Following the completion of the transaction, the chief financial officer now owns 2,000 shares in the company, valued at approximately $30,000. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jeffrey G. Park bought 3,000 shares of Diplomat Pharmacy stock in a transaction dated Monday, November 20th. The shares were bought at an average cost of $15.46 per share, for a total transaction of $46,380.00. Following the completion of the transaction, the director now owns 7,640 shares of the company’s stock, valued at approximately $118,114.40. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 15,000 shares of company stock worth $228,780. Corporate insiders own 30.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “110,225 Shares in Diplomat Pharmacy, Inc. (DPLO) Purchased by Sterling Capital Management LLC” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.watchlistnews.com/110225-shares-in-diplomat-pharmacy-inc-dplo-purchased-by-sterling-capital-management-llc/1770938.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.